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Introduction
Spinocerebellar ataxia 7 (SCA7) is a progressive autosomal 
dominant neurodegenerative disorder characterized by cerebel-
lar ataxia and visual impairment (David et al., 1997) that is due 
to moderate to severe neuronal loss in the cerebellum and asso-
ciated structures (Cancel et al., 2000) and degeneration of cone 
and rod photoreceptors. The SCA7 gene product, ataxin-7 
(ATXN7), is a component of the TBP-free TAF-containing 
complex (TFTC) and the SPT3/TAF9/GCN5 acetyltransferase 
complex (STAGA), which are implicated in several steps of 
transcriptional regulation, such as histone acetylation and 
  recruitment of the preinitiation complex to promoters (Scheel 
et al., 2003; Helmlinger et al., 2004b).
SCA7 belongs to a group of nine inherited neurodegener-
ative disorders caused by an unstable CAG repeat expansion in 
gene coding regions, leading to the elongation of a polyglutamine 
(polyQ) tract in the respective proteins (Stevanin et al., 2002). 
PolyQ expansions confer toxic properties on mutant pro-
teins, which accumulate aberrantly in neurons, leading to the 
formation of insoluble nuclear inclusions (NIs), a hallmark of 
polyQ diseases.
Analysis of mouse models of polyQ disorders showed that 
accumulation in neuronal nuclei of proteins with expanded polyQ 
is an important step in pathogenesis (Yvert et al., 2001; Watase 
et al., 2002; Goti et al., 2004). In SCA7 transgenic and knockin 
mouse models, progressive retinal degeneration correlates with 
nuclear accumulation of mutant ATXN7 and altered transcription 
of photoreceptor genes (La Spada et al., 2001; Yoo et al., 2003; 
Helmlinger et al., 2004a). Several mechanisms have been 
  proposed to underlie polyQ toxicity in the nucleus (Michalik and 
Van Broeckhoven, 2003), including sequestration into NIs of 
  nuclear proteins, such as transcription factors, nuclear body com-
ponents, constituents of the ubiquitin-proteasome system (UPS) 
and chaperones, which might impair their functions. In the case 
of SCA7, it was recently shown that mutant ATXN7 alters the 
functions of the TFTC and STAGA complexes (McMahon et al., 
2005; Palhan et al., 2005; Helmlinger et al., 2006).
PML clastosomes prevent nuclear accumulation 
of mutant ataxin-7 and other polyglutamine proteins
Alexandre Janer,
1,2,3 Elodie Martin,
1,2,3 Marie-Paule Muriel,
1,2,3 Morwena Latouche,
1,2,3 Hiroto Fujigasaki,
6 
Merle Ruberg,
1,2,3 Alexis Brice,
1,2,3,4 Yvon Trottier,
5 and Annie Sittler
1,2,3
1Institut National de la Santé et de la Recherche Médicale U679, Neurologie et Thérapeutique Expérimentale, 75651 Paris Cedex 13, France
2Hôpital de la Pitié-Salpêtrière, 75651 Paris Cedex 13, France
3Faculté de Médecine, Université Pierre et Marie Curie, 75651 Paris Cedex 13, France
4Département de Génétique, Cytogénétique et Embryologie, Groupe Hospitalier Pitié-Salpêtrière, 75651 Paris Cedex 13, France
5Département de Pathologie Moléculaire, Institut de Génétique et Biologie Moléculaire et Cellulaire, Institut National de la Santé et de la Recherche Médicale, 
Centre National de la Recherche Scientiﬁ  que, Université Louis Pasteur, BP 10142, Illkirch Cedex, CU de Strasbourg, France
6Department of Neurology, Musashino Red Cross Hospital, Tokyo 108-8339, Japan
T
he pathogenesis of spinocerebellar ataxia type 7 
and other neurodegenerative polyglutamine (polyQ) 
disorders correlates with the aberrant accumulation 
of toxic polyQ-expanded proteins in the nucleus. 
  Promyelocytic leukemia protein (PML) nuclear bodies are 
often present in polyQ aggregates, but their relation to 
pathogenesis is unclear. We show that expression of PML 
isoform IV leads to the formation of distinct nuclear bodies 
enriched in components of the ubiquitin-proteasome 
  system. These bodies recruit soluble mutant ataxin-7 and pro-
mote its degradation by proteasome-dependent proteolysis, 
thus preventing the aggregate formation. Inversely, disrup-
tion of the endogenous nuclear bodies with cadmium 
  increases the nuclear accumulation and aggregation of 
mutant ataxin-7, demonstrating their role in ataxin-7 
  turnover. Interestingly, β-interferon treatment, which in-
duces the expression of endogenous PML IV, prevents the 
accumulation of transiently expressed mutant ataxin-7 
without affecting the level of the endogenous wild-type 
protein. Therefore, clastosomes represent a   potential ther-
apeutic target for preventing polyQ disorders.
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Accumulation of polyQ-expanded proteins in the nucleus 
may be due to a defect in protein folding, turnover, or degradation. 
As neurons are postmitotic and long-lived cells, failure to 
prevent the accumulation of toxic proteins may compromise 
their survival. Accordingly, molecules that prevent nuclear 
  accumulation or increase the clearance of misfolded polyQ 
proteins were protective against polyQ toxicity in mouse 
models (Sanchez et al., 2003; Tanaka et al., 2004; Waza et al., 
2005). An understanding of the mechanisms whereby mutant 
proteins accumulate, aggregate, or are eliminated in the nucleus 
would help in the development of therapeutic strategies for 
these diseases.
Previous studies showed that promyelocytic leukemia 
protein (PML) nuclear bodies colocalized with polyQ- containing 
proteins in nuclear matrix preparations of cells expressing 
ATXN7 or ataxin-1 (Skinner et al., 1997; Kaytor et al., 1999). 
Furthermore, the normal nuclear distribution of PML was 
  altered by the expression of mutant ataxin-1 and -3 (Skinner et al., 
1997; Chai et al., 1999). In the brains of patients with SCA7 or 
other polyQ disorders, PML bodies often colocalized with neu-
ronal NIs (Takahashi et al., 2003). Interestingly, colocalization 
of PML bodies occurred more frequently in small than in large 
NIs (Takahashi et al., 2002), suggesting that PML bodies are 
associated with early steps of polyQ protein aggregation.
PML bodies are multiprotein complexes distributed in a 
speckled pattern throughout the nucleus (Jensen et al., 2001; 
Negorev and Maul, 2001; Borden, 2002), where they have been 
suggested to play a role in many cellular processes, such as tran-
scriptional regulation, growth control, and apoptosis (Seeler 
and Dejean, 1999; Zhong et al., 2000). The heterogeneous com-
position and morphology of PML bodies has led to the sugges-
tion that the different PML isoforms have distinct cellular 
functions (Beech et al., 2005). Because of the variety of partner 
proteins found in PML bodies, it has also been proposed that 
PML bodies might be storage compartments for nuclear  proteins 
(Negorev and Maul, 2001). However, clastosomes, a subset of 
PML bodies, contain components of the UPS and were sug-
gested to be sites of protein degradation in the nucleus (Lafarga 
et al., 2002). Clastosomes appear to be transient structures that 
assemble when proteolysis is highly active in the nucleus but 
disappear when the proteasome is inhibited (Lafarga et al., 
2002). Interestingly, Muratani et al. (2002) showed that some 
PML bodies move about rapidly in the nucleus in an energy-
  dependent fashion and suggested that these dynamic PML bodies 
may be nuclear sensors of foreign or misfolded proteins, includ-
ing those of viral origin, and would thus act like a subnuclear 
immune system. This is consistent with the observation that 
  interferon (INF) induces PML expression and stimulates the 
formation of PML bodies (Regad and Chelbi-Alix, 2001).
In this study, we aimed at understanding the role of PML 
bodies in the fate of polyQ-expanded ATXN7 in the nucleus. 
Modifying the level and composition of PML bodies dramati-
cally affects the aggregation of mutant ATXN7. We show that a 
specifi  c isoform of PML, PML IV, orchestrates the recruitment 
of components of the UPS, chaperones, and mutant ATXN7 
(and other expanded polyQ proteins) in specialized nuclear 
bodies that resemble clastosomes to promote their degradation. 
The capacity of the nucleus to degrade proteins can be modulated 
to prevent the toxic accumulation of expanded polyQ proteins.
Results
Aggregated ATXN7 colocalizes with PML 
bodies in SCA7 transgenic mice
We previously showed that PML bodies colocalized with a sub-
set of polyQ aggregates in the brains of patients with SCA7 
(Takahashi et al., 2002). To determine whether this was also the 
case in models of SCA7, we examined the brains of transgenic 
mice B7E2.B, which express mutant ATXN7 with 128 gluta-
mines ubiquitously in the central nervous system and develop 
progressive ataxia (Yvert et al., 2001). Mutant ATXN7 accumu-
lated in most neurons, including the cerebellar Purkinje cells 
(Fig. 1 a) and retinal neurons (Fig. 1, b–d), leading to NI 
formation. A subset of large ATXN7 aggregates in Purkinje 
cells (Fig. 1 a) and retinal ganglion neurons (Fig. 1 b) contained 
PML bodies. Ganglion neurons also had small ATXN7 aggre-
gates, which were either sparsely distributed in the nucleus or 
juxtaposed to large aggregates. PML bodies colocalized with 
Figure 1.  ATXN7 aggregates colocalize with PML bodies in SCA7 trans-
genic mice. Immunoﬂ   uorescence analysis of cerebellar Purkinje cells (a) 
and retinal ganglion neurons (b–d) using antibodies against ATXN7 
  (afﬁ  nity-puriﬁ   ed polyclonal antibody 1261) and PML (chicken anti-PML 
  antibody). Large ATXN7 aggregates sequestered PML bodies (a and b). 
In ganglion neurons, PML bodies were also surrounded by (b, yellow   arrows), 
colocalized with (c, arrowheads), or juxtaposed to (d, white arrows) small 
ATXN7 aggregates. The same ganglion neuron on two different focal 
plans, shown in panels c and d, displayed distinct colocalization between 
PML bodies and ATXN7 aggregates. Bars, 5 μm.PML IV DEGRADES MUTANT ATXN7 • JANER ET AL. 67
small aggregates, in some cases forming a ring around the 
  aggregate (Fig. 1, b, c, and d). Some PML bodies were juxtaposed 
to both small and large aggregates (Fig. 1 d). Colocalization of 
PML bodies with ATXN7 aggregates, notably small ones, is 
consistent with our previous study of SCA7 brains and raises 
the question of how PML bodies affect the aggregation of 
 mutant ATXN7.
ATXN7 colocalizes with PML bodies 
in cell culture models
To investigate the relationship between PML bodies and mutant 
ATXN7, we coexpressed full-length wild-type and mutant 
ATXN7 with isoforms of PML in neurons and in COS-7 cells. 
There are seven isoforms of PML, resulting from differential 
splicing, that form nuclear bodies with different morphologies 
(Bischof et al., 2002; Beech et al., 2005). We have examined the 
effect of exogenous expression of PML IV, which was previ-
ously shown to induce cellular senescence, apoptosis, and regu-
late p53 activity (Fogal et al., 2000; Bischof et al., 2002) and 
may thus be related to neuronal dysfunction or death. The 
  effects of PML III were examined to control for specifi  city.
Endogenous ATXN7 was distributed homogeneously in 
a granular pattern throughout the nucleus and did not colocal-
ize with the small endogenous nuclear bodies observed in 
neurons (Fig. 2 A, a–c). When PML IV was overexpressed in 
transfected neurons, both endogenous ATXN7 (Fig. 2 A, d–f) 
and full-length wild-type (FL-10Q) exogenous ATXN7 (Fig. 
2 A, g–i) colocalized with PML IV in larger nuclear bodies. 
In COS-7 cells, mutant ATXN7 with 74Q (FL-74Q) was also 
distributed homogeneously in the nucleoplasm of the majority 
of transfected cells when expressed alone (unpublished data). 
In 10–20% of the cells, however, multiple dense nuclear 
  aggregates were seen that contained endogenous PML bodies 
in their center (Fig. 2 B, a–c), as well as the Daxx protein, a 
resident PML body protein (not depicted). Exogenous PML 
III formed rod-shaped bodies and exogenous PML IV larger 
patchy structures, some of which had a ring-like shape 
  (unpublished data). When PML III was coexpressed with 
FL-74Q, both rod-shaped PML III bodies and ATXN7 aggre-
gates were observed, but they rarely colocalized (Fig. 2 B, d–f). 
In contrast, PML IV and mutant ATXN7 colocalized in large, 
rounder nuclear structures (Fig. 2 B, g–i) that differed from 
the dense ATXN7 aggregates but resembled the PML IV bod-
ies in that some had a ring-like shape (Fig. 2 B, h, arrow-
heads). In primary cultures of rat cortical neurons, PML IV 
also formed round nuclear bodies, but they were smaller 
and morphologically more homogenous than in COS-7 cells 
(Fig. 2 A, d–f). When mutant ATXN7 and PML IV were coex-
pressed in these neurons (Fig. 2 B, j–l), mutant ATXN7 was 
localized in the PML IV bodies. These data suggest that PML 
IV bodies recruit both endogenous ATXN7 and exogenous 
normal and mutant ATNX7.
PML IV recruits soluble mutant ATXN7 
to nuclear bodies
To determine whether PML IV recruits ATXN7 to the nuclear 
bodies, we performed video-recorded time-lapse experiments 
Figure 2.  PML isoform IV relocalizes both endogenous and exogenous 
wild-type and mutant ATXN7. (A) In untransfected cortical neurons (NT), 
endogenous PML (a) did not colocalize with endogenous ATXN7 (b); note 
that endogenous nuclear bodies, which can be very small, are not detected 
in all neurons. Overexpressed PML IV relocalized both endogenous ATXN7 
(d–f) and overexpressed wild-type ATXN7 (FL-10Q; g–i) to PML IV bodies. 
(B) In COS-7 cells, full-length mutant ATXN7 (FL-74Q) partially colocalized 
with endogenous PML bodies (a–c) and did not colocalize with PML III (d–f) 
but colocalized with PML IV in large round PML bodies (g–i), some with a 
ring-like pattern (h, arrowheads). In cortical neurons, FL-74Q and PML IV 
were also colocalized (j–l). Antibodies used were anti–ATXN7 1C1 and 
polyclonal anti-PML. Confocal images are shown. Bars, 5 μm.JCB • VOLUME 174 • NUMBER 1 • 2006  68
on living HeLa Kyoto cells expressing full-length ATXN7 with 
100Q fused to EGFP (EGFP-FL-100Q) and PML IV fused to 
RFP. The cells were monitored from 6 to 22 h after transfec-
tion (i.e., for 16 h). Fig. 3 illustrates the development of 
ATXN7-containing PML bodies over a period of 6 h and 40 min. 
In cells expressing EGFP-FL-100Q alone, the intensity of 
the green fl  uorescence increased over time up to 22 h after 
transfection but remained homogeneously distributed in the 
nucleoplasm (unpublished data), indicating that endogenous 
PML bodies do not form ATXN7-positive bodies. In the pres-
ence of RFP-PML IV (red), EGFP-FL-100Q fl  uorescence 
  remained weak in the nucleoplasm but increased in PML IV 
bodies from the moment they formed (Fig. 3), indicating that 
the soluble form of mutant ATXN7 was recruited to the PML 
IV bodies. Small ATXN7-containing PML IV bodies then 
moved and coalesced into larger bodies. PML IV, therefore, 
recruits soluble mutant ATXN7 to nascent PML IV bodies, 
preventing its accumulation in the nucleus and formation 
of focal aggregates. Coalescence of small bodies into larger 
ones was also observed in cells expressing RFP-PML IV alone 
(unpublished data).
ATXN7 interacts with PML IV
To determine whether recruitment of ATXN7 to PML IV bodies 
was due to a physical interaction with PML IV in cell nuclei, we 
performed coimmunoprecipitation experiments. We fi  rst veri-
fi  ed that two different anti-PML antibodies (monoclonal and 
polyclonal) immunoprecipitated PML IV (Fig. 4 A, lanes 2 and 3) 
and that the anti-ATXN7 monoclonal antibody 1C1 immuno-
precipitated FL-10Q (Fig. 4 C, lane 2) and FL-74Q (Fig. 4 B, 
lane 2). The control antibodies (anti-myc and anti-Xpress) did 
not immunoprecipitate either protein (Fig. 4, A [lanes 4, 5, and 7] 
and B [lanes 3, 6, and 7]). When HA-tagged FL-74Q and PML 
IV were coexpressed and ATXN7 was immunoprecipitated with 
1C1, PML IV coprecipitated in the complex (Fig. 4 A, lane 6). 
When PML IV was immunoprecipitated, HA-tagged FL-74Q 
coprecipitated in the complex (Fig. 4 B, lanes 4 and 5). FL-10Q 
and PML IV also coimmunoprecipitated (Fig. 4 C, lane 3). 
Therefore, not only mutant full-length ATXN7 but also its wild-
type counterpart physically interact, directly or indirectly, with 
PML IV in nuclear bodies.
PML IV bodies degrade mutant ATXN7 
and prevent aggregate formation
We then determined the effect of PML IV on the biochemical 
properties of mutant ATXN7. When FL-74Q alone was 
  expressed in COS-7 cells, both soluble and aggregated ATXN7 
were detected. The soluble form of mutant ATXN7 appeared 
as a 150-kD protein on Western blots (Fig. 5 A, top). 
Figure 3.  PML IV rapidly recruits soluble mutant ATXN7 from nucleoplasm 
to PML IV bodies. Time-lapse imaging of living HeLa Kyoto cells expressing 
EGFP-FL-100Q and RFP-PML IV. 6 h after transfection, cells expressing low 
levels of EGFP-FL-100Q were monitored every 10 min for a period of 16 h. 
A series of representative images taken during a 6-h, 40-min time period 
is shown. From the moment PML IV bodies (red) formed (2 h, 10 min), 
EGFP-FL-100Q (green) relocalized from the nucleoplasm to these tiny red 
dots. At 4 h, 20 min, small PML IV bodies coalesced into larger bodies and 
recruited more EGFP-FL-100Q. At 6 h, 40 min, fusion of ATXN7-containing 
PML IV bodies was more pronounced, preventing ATXN7 accumulation in 
the nucleoplasm. Bar, 10 μm.
Figure 4.  ATXN7 interacts with PML IV. (A and B) Mutant (FL-74Q) 
or wild-type (FL-10Q) ATXN7 and PML IV were coexpressed in COS-7
cells and immunoprecipitated (IP) or coimmunoprecipitated (Co-IP). 
  Antibodies used were as follows: 1C1 monoclonal anti-ATXN7, PML 
monoclonal (PMLm), PML polyclonal (PMLp), anti-Xpress (monoclonal 
negative control), and anti-Myc (polyclonal negative control). (A) Immuno-
precipitation of PML IV (lanes 2 and 3) and coimmunoprecipitation of 
PML IV with ATXN7 (lane 6). Coimmunoprecipitation was not seen with 
control antibodies (lanes 4, 5, and 7). (B) Immunoprecipitation of   mutant 
ATXN7 (FL-74Q; lane 2) and coimmunoprecipitation with PML (lanes 
4 and 5). Coimmunoprecipitation was not seen with control antibodies 
(lanes 3, 6, and 7). (C) Immunoprecipitation of FL-10Q (lane 2) and co-
immunoprecipitation with PML IV (lane 3). Coimmunoprecipitation was not 
seen with the control antibody (lane 4). The lanes shown in each panel 
were on the same blots; cuts were made to eliminate lanes irrelevant to 
the demonstration.PML IV DEGRADES MUTANT ATXN7 • JANER ET AL. 69
The   aggregated form of the protein was retained on cellulose 
 acetate  fi  lters in the fi  lter retardation assay (Fig. 5 A, bottom), 
which evaluates the overall amount of SDS-insoluble amyloid 
fi  bers formed by the aggregation of proteins with expanded 
polyQ (Wanker et al., 1999). Aggregated ATXN7 was found in 
the pellet when cell homogenates were centrifuged but not in 
the supernatant. Coexpression with PML III very slightly in-
creased the amounts of soluble and aggregated ATXN7 (Fig. 5 A, 
top and bottom). In contrast, coexpression with PML IV led to 
a strong decrease in the amounts of soluble and aggregated 
ATXN7 (Fig. 5 A, top and bottom). The supernatant obtained 
after centrifugation of cell homogenates was also devoid of 
SDS-insoluble ATXN7. The difference between the effects of 
PML III and IV was not due to different levels of expression of 
the isoforms (Fig. 5 A, top) or to differential effects on the tran-
scription of the ATXN7 gene (Fig. 5 B). This suggests that 
PML IV bodies act directly on the ATXN7 protein by  increasing 
its degradation.
We then examined whether PML IV–dependent degrada-
tion of ATXN7 depends on the length of the polyQ tract. When 
expressed with PML IV, the level of wild-type FL-10Q also 
  decreased (Fig. 5 C), whereas its level slightly increased when 
expressed in the presence of PML III. Degradation therefore 
does not depend on the presence of an expanded polyQ tract.
To determine whether PML IV bodies also degrade 
other polyQ-containing proteins, we coexpressed PML IV 
with   huntingtin (Htt)-exon1 harboring 125Q. PML IV strongly 
  reduced the level of soluble mutant Htt-exon1 (Fig. 5 D). 
We also verifi  ed whether PML IV would degrade an unrelated nu-
clear protein, fragile X mental retardation protein (FMRP; Sittler 
et al., 1996) without a polyQ sequence. The level of expres-
sion of exogenous FMRP was unaffected by coexpression with 
PML IV (Fig. 5 E). Intriguingly, a second faint band of lower 
molecular mass appeared to be decreased by PML IV. Its iden-
tity is unknown.
These results show that PML IV bodies recruit both exog-
enous mutant and normal polyQ-containing proteins and pre-
vent their accumulation in the nucleus but have no effect on 
another exogenous nuclear protein, FMRP, showing that PML 
IV targets were not degraded because they were mutated or 
overexpressed. The targets of PML IV are therefore selective, 
although the basis for the selectivity is not known.
PML IV promotes the degradation 
of mutant ATXN7 by proteasomes
To determine whether PML IV increased the rate of degradation 
of mutant ATXN7, we performed pulse-chase experiments in 
COS-7 cells in which mutant ATXN7 was expressed either 
alone or in combination with PML IV. The degradation of 
  mutant ATXN7 expressed alone was relatively slow, in good 
agreement with a previously published pulse-chase experiment 
(Yvert et al., 2001). During the fi  rst 8 h of the chase period, only 
28% of ATXN7 was degraded (Fig. 6 A). In the presence of 
PML IV, however, 83% of mutant ATXN7 was degraded after 
8 h (Fig. 6 A). The difference between the levels of ATXN7 in 
the presence and in the absence of PML IV was signifi  cant at all 
time points, starting at 2 h, indicating that PML IV bodies 
  accelerate the degradation of mutant ATXN7.
To see whether the degradation of mutant ATXN7 in the 
presence of PML IV was mediated by proteasomes, COS-7 
cells expressing FL-74Q in the presence and in the absence of 
PML IV were treated with 5 μM of the proteasome inhibitor 
MG132. Inhibition of the proteasome increased the amount of 
mutant ATXN7 in the cells coexpressing FL-74Q and PML IV 
(Fig. 6 B, compare third and fourth lanes). However, because 
PML IV was already active before MG132 treatment, it was not 
possible to accumulate ATXN7 to the level observed without 
PML. MG132 also increased the level of mutant ATXN7 
  expressed in the absence of PML IV by impeding normal turnover 
Figure 5.  ATXN7 and Htt-exon1 are efﬁ  ciently degraded in the   presence 
of PML IV. (A) Western blot and ﬁ   lter assay of FL-74Q alone or coex-
pressed with PML IV or III in COS-7 cells. (top) Western blot (30 μg 
protein, anti–ATXN7 1C1, and anti–PML polyclonal). ATXN7 levels 
strongly decreased in the presence of PML IV (lane 2) but slightly increased 
with PML III (lane 3). (bottom) Pellet (P) or supernatant (S) fractions of cell 
extracts (30 μg protein) were ﬁ  ltered, and SDS-insoluble ATXN7 was re-
vealed by anti–ATXN7 1C1. Coexpression of PML IV led to the disappear-
ance of SDS-insoluble aggregates of mutant ATXN7 (lane 2), whereas PML 
III slightly increased ATXN7 (lane 3 compared with lane 1). (B) RT-PCR. 
mRNAs were extracted from cells expressing FL-74Q alone (lane 1) or 
combined with PML IV (lane 2) or III (lane 3). Primers speciﬁ  c to the SCA7 
cDNA and the cyclophilin A (Cyclo A) reference cDNA were used for 
PCR. Coexpression of PML IV or III had no effect on mutant ATXN7 mRNA. 
(C) Western blot of cells expressing FL-10Q alone (lane 1) or coexpressed 
with PML IV (lane 2) or III (lane 3). PML IV decreased and PML III slightly 
increased ATXN7 levels (same antibodies as in A). (D) Western blot of 
  mutant Htt-exon1 expressed in HeLa cells; Htt-exon1 (Ex1) with 125Q 
alone (lane 1) or with PML IV (lane 2). Levels of Htt-exon1 (detected with 
antibody 1C2) were strongly decreased when PML IV was coexpressed. 
(E) Western blot of FMRP expressed in COS-7 cells alone (lane 1) or with 
PML IV (lane 2). PML IV did not modify the amount of overexpressed FMRP 
(detected with antibody 1C3). The asterisk indicates unknown protein 
  degraded in the presence of PML IV. In C, D, and E, the anti-PML antibody 
was the same as in A.JCB • VOLUME 174 • NUMBER 1 • 2006  70
of the protein (Fig. 6 B, compare fi  rst and second lanes). We 
thus conclude that the effect of PML IV on the degradation of 
ATXN7 was mediated by the UPS.
PML IV bodies recruit UPS components 
to degrade mutant ATXN7
Under certain stress conditions, PML forms clastosomes that 
contain components of the UPS (Lafarga et al., 2002). 
To   determine whether PML IV bodies are clastosomes and to 
under stand how they may clear ATXN7, they were analyzed 
for the presence of UPS components. S10a, a subunit of the 
19S non-ATPase regulatory complex of the proteasome was 
not found in focal aggregates formed by mutant ATXN7 (Fig. 7 A, 
a–c) but was highly colocalized with PML IV bodies when only 
PML IV was expressed (Fig. 7 A, d–f). Interestingly, when 
  coexpressed with PML IV, mutant ATXN7 colocalized perfectly 
Figure 6.  PML IV promotes the degradation 
of mutant ATXN7 by proteasomes. (A) Pulse-
chase analysis of the turnover of FL-74Q 
  expressed alone or with PML IV in COS-7 cells. 
Quantiﬁ  cation of immunoprecipitated ATXN7 
from four independent experiments are ex-
pressed as means ± SEM. *, P ≤ 0.002; 
**, P ≤ 0.001 (paired t test). #, P ≤ 0.03 
(Mann-Whitney test). (B) Inhibition of the prote-
asome by MG132 (5 μM) treatment in COS-7 
cells signiﬁ  cantly increases the amount of FL-74Q 
expressed alone (compare ﬁ   rst and second 
lanes) or with PML IV (compare third and fourth 
lanes). The asterisk indicates longer exposure 
of the same blot. (bottom) PML IV levels.
Figure 7. PML IV bodies recruit UPS 
  components. (A) S10a, a subunit of the 19S 
  regulatory complex of the proteasome, was 
not found in focal aggregates formed by 
  mutant ATXN7 (a–c) but was highly colocal-
ized with PML IV bodies when only PML IV was 
expressed (d–f). When coexpressed with PML 
IV, mutant ATXN7 colocalized perfectly with 
the S10a subunit in PML IV bodies (g–i). 
(B) The 20S catalytic core of the proteasome 
faintly colocalized with some ATXN7 aggre-
gates (a–c) but strongly   colocalized with PML 
IV expressed alone (d–f) and with ATXN7 pre-
sent in PML IV bodies (g–i) when both proteins 
are coexpressed. (C) The Hsp40 chaperone 
was found in some ATXN7 aggregates (a–c) 
but to a much greater extent in PML IV bodies 
(d–f). Hsp40 also strongly   colocalized with 
ATXN7 when it is relocalized in PML IV bodies 
(g–i). Confocal images are shown. (D) Poly-
ubiquitinylated proteins (labeled with the FK2 
antibody) were enriched in PML IV bodies con-
taining ATXN7. Untransfected cells (NT; a–c) 
contain a subset of endogenous PML bodies 
(c, arrowheads) that colocalized with poly-
ubiquitinylated proteins. Aggregates of mutant 
ATXN7 expressed alone (d–f) colocalized 
faintly with polyubiquitinylated proteins but 
strongly colocalized with polyubiquitinylated 
proteins when recruited in PML IV bodies (g–i). 
Conventional ﬂ   uorescence was used in D. 
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with the S10a subunit in PML IV bodies (Fig. 7 A, g–i). Simi-
lar observations were made with two other 19S proteasome 
subunits, S5a and S6b (Fig. S1, A and B, available at 
http://www.jcb.org/cgi/content/full/jcb.200511045/DC1); the 
latter was already detected in endogenous clastosomes (Lafarga 
et al., 2002). The 20S catalytic core of the proteasome colo-
calized only with a subset of aggregates in cells expressing 
FL-74Q alone (Fig. 7 B, a–c), but colocalization was complete 
with PML IV bodies containing the mutant protein (Fig. 7 B, 
g–i), as well as with PML IV expressed alone (Fig. 7 B, d–f). 
This was also observed for subunit α2 of the 20S proteasome 
(Fig. S1 C). The same was true for the chaperone Hsp40, 
which recognizes misfolded polyQ proteins (Fig. 7 C). 
We next verifi  ed whether ATXN7 was ubiquitinylated in PML 
IV bodies. Nontransfected cells possessed only a few PML 
 bodies  labeled with an antibody against polyubiquitin that were 
possibly endogenous clastosomes (Fig. 7 D, a–c, arrowheads 
indicate colocalization). Aggregates of ATXN7, when ex-
pressed alone (Fig. 7 D, d–f), were only slightly labeled with 
the anti-  polyubiquitin antibody, but ATXN7-containing PML IV 
bodies were strongly labeled (Fig. 7 D, g–i). Together, these 
data   indicate that PML IV induces the assembly of a nuclear 
  structure dedicated to protein degradation, reminiscent of 
clastosomes. They recruit both chaperones and proteasomes 
together with its substrates, such as mutant ATXN7, targeted 
for degradation by polyubiquitin.
Recruitment of mutant ATXN7 
in PML IV bodies prevents polyQ amyloid 
ﬁ  ber formation
We investigated the nature of mutant ATXN7 in PML IV bod-
ies by performing an ultrastructural analysis of transfected 
COS-7 cells. Because truncated mutant ATXN7 aggregates 
more rapidly than the full-length protein (unpublished data), 
we expressed Tr-100Q-EGFP (the fi  rst 232 amino acids of the 
protein containing the polyQ stretch fused to EGFP) in the 
presence or absence of PML IV. We examined ATXN7 distri-
bution by electron microscopy after immunolabeling with a 
monoclonal anti-ATXN7 antibody and a secondary antibody 
coupled with 10-nm gold particles. Tr-100Q-EGFP, when 
  expressed alone, was restricted to pale-stained fi  brillary struc-
tures in the nucleus with fi  bers radiating from the edges of the 
aggregates (Fig. 8, A and B). When coexpressed with PML IV, 
Tr-100Q-EGFP colocalized with PML IV (colabeling with 
species-specifi  c secondary antibodies coupled with 15-nm gold 
particles to detect PML) in round or oval structures, which 
are most likely PML IV bodies (Fig. 8, C and D; arrows 
[ATXN7] and arrowheads [PML] indicate colocalized gold 
particles). Importantly, no fi  brillary structures were evident in this 
case (Fig. 8, C and D). This was confi  rmed by the absence 
of ATXN7 aggregates on the fi  lter assay (Fig. 8 E). ATXN7 
in PML IV bodies was therefore no longer fi  brillary  in 
structure and can no longer be considered to be aggregated. 
Figure 8.  PML IV prevents the formation of ﬁ  brillar struc-
tures of mutant truncated ATXN7. (A–D) Immunoelectron 
  microscopic images of COS-7 cells expressing Tr-100Q-EGFP 
alone (A and B) or in combination with PML IV (C and D). The 
following primary antibodies were used: anti–ATXN7 1C1 
(mouse) and anti-PML (rabbit). The following secondary anti-
bodies were used: anti-mouse or anti-rabbit immunoglobulins 
coupled to 10- or 15-nm gold particles, respectively. ATXN7 
(10-nm particles) is seen inside an intranuclear inclusion (A) 
surrounded by long ﬁ  bers (higher magniﬁ  cation in B). (C and 
D) When both PML IV and mutant ATXN7 are expressed, 
  colocalization is observed between ATXN7 (10-nm particles, 
arrows) and PML (15-nm particles, arrowheads). In double-
transfected cells, no ﬁ  bers can be detected. Nuclear membrane 
is visible in A (top). Bars: (A and C) 1 μm; (B and D) 0.5 μm. 
(E) Western blot and ﬁ  lter assay of extracts of cells expressing 
Tr-100Q-EGFP expressed alone or with PML IV. Coexpression 
of PML IV led to a modest decrease in the level of soluble 
Tr-100Q (Western blot) but to a strong decrease in the amount 
of SDS-insoluble Tr-100Q (ﬁ  lter assay).JCB • VOLUME 174 • NUMBER 1 • 2006  72
Soluble Tr-100Q-EGFP levels analyzed on Western blot were 
slightly decreased by PML IV expression (Fig. 8 E).
Cadmium disrupts PML bodies 
and prevents the degradation of mutant 
ATXN7 by endogenous clastosomes
To determine whether altering the amount of endogenous PML 
bodies affects the degradation or aggregation of mutant ATXN7, 
we treated cells expressing FL-74Q with cadmium chloride, 
  reported to disrupt PML bodies (Nefkens et al., 2003). Immuno-
fl   uorescence analysis showed that 2 μM cadmium totally 
disrupted the endogenous PML bodies. Consequently, no colo-
calization between mutant ATXN7 aggregates and the PML 
protein was observed (Fig. 9 A, d–f), compared with the 
  untreated cells (Fig. 9 A, a–c). A treatment with increasing 
  concentrations of cadmium (0.25–2 μM) showed that the 
  aggregation of mutant ATXN7 was dose dependent, as shown 
on fi  lter assay (Fig. 9 B), suggesting that endogenous clasto-
somes are indeed involved in mutant ATXN7 degradation.
𝗃-INF stimulates the PML-dependent 
degradation of mutant ATXN7 
and the disappearance of aggregates
Because β-INF was reported to up-regulate the expression of 
PML (Regad and Chelbi-Alix, 2001), we investigated its effect 
on the PML-dependent degradation of mutant ATXN7. β-INF 
increased the size and number of PML bodies in nontransfected 
COS-7 cells (Fig. 10 A, a and b). Faint endogenous PML 
  immunoreactivity was observed in aggregates of mutant ATXN7 
in untreated cells (Fig. 10 A, c–e, arrowheads). β-INF  treatment 
led to the formation of large, strongly immunoreactive PML 
bodies that colocalized with mutant ATXN7 (Fig. 10 A, f–h). 
These results also suggest that the presence of mutant ATXN7 
promoted the coalescence and fusion of PML bodies into 
  enlarged bodies resembling PML IV bodies, which colo-
calized perfectly with mutant ATXN7 (Fig. 10 A, compare b 
and g). Semiquantitative RT-PCR performed with primers that 
 specifi  cally amplify PML IV showed that the expression of 
PML IV was induced in β-INF–treated cells but not in control 
cells (Fig. 10 B, lane 2). Western blots show that β-INF 
  increased the levels of several PML isoforms in both untrans-
fected COS-7 cells and cells overexpressing exogenous ATXN7 
in its wild-type FL-10Q or mutant form FL-74Q (Fig. 10, C–E). 
β-INF treatment decreased the amount of overexpressed solu-
ble FL-10Q (Fig. 10 D) and FL-74Q (Fig. 10 E) but had no ef-
fect on the level of endogenous wild-type ATXN7 (Fig. 10 C). 
The PML-dependent degradation of ATXN7 induced by β-INF 
was mediated by the proteasome, as it was inhibited by MG132 
(Fig. 10 F). Interestingly, insoluble mutant ATXN7 disappeared 
from cells treated with β-INF, as shown by the fi  lter assay, but 
an insoluble PML-containing material was detected (Fig. 10 G, 
left, lane 2). This material was independent of ATXN7 expres-
sion but dependent on β-INF treatment and attributable to the 
increased expression of PML IV isoform (Fig. 10 G, right, 
lanes 2 and 3).
We conclude from these experiments that β-INF induces 
PML IV expression and increases the presence of clastosomes 
that degrade ATXN7, preventing its aggregation. The observa-
tion that only mutant but not endogenous ATXN7 is degraded in 
the presence of β-INF suggests that this substance may have 
therapeutic value.
Discussion
Accumulation of misfolded polyQ-expansion proteins in neuro-
nal nuclei, ultimately leading to the formation of NIs, is a key 
step in the pathogenesis of SCA7 and other polyQ-expansion 
diseases (Michalik and Van Broeckhoven, 2003). We have 
  focused on PML bodies, known to be associated with NIs 
  (Takahashi et al., 2003), which are suggested to be privileged 
sites of nuclear protein degradation (Lafarga et al., 2002), and 
have investigated their role in either the degradation or the 
  accumulation of polyQ-containing protein. We report that 
  modifying the level and composition of PML nuclear bodies has 
profound effects on the fate of disease-causing polyQ- expansion 
proteins in the nucleus.
Seven PML isoforms have been described that share 
an NH2-terminal region comprising the RBCC (RING-fi  nger, 
B-box, coiled-coil domain) but differ in their COOH-terminal 
region because of alternative splicing (Jensen et al., 2001). The 
role of each isoform is not yet known, but they might be associ-
ated with different functions of the nuclear bodies (Bischof 
et al., 2002; Muratani et al., 2002; Beech et al., 2005). We have 
explored the effect of two isoforms, PML III and IV, on the fate 
of mutant ATXN7 in the nucleus. Although these isoforms differ 
only by their short COOH-terminal extensions (71 amino acids 
in PML III and 63 amino acids in PML IV), they form nuclear 
Figure 9.  Cadmium disrupts PML bodies and enhances aggregation of 
mutant ATXN7. (A) In untreated COS-7 cells, mutant ATXN7 colocalizes 
with endogenous PML bodies (a–c). In cells treated with 2 μM cadmium (d–f), 
PML bodies are disrupted and no longer visible (e). Consequently, large 
ATXN7 aggregates cannot contain any PML bodies (f). (B) The increase in 
ATXN7 aggregation is dose dependent in cells treated with 0.25–2 μM 
cadmium (ﬁ  lter assay on pellet fraction of cell extracts; 50 μg).PML IV DEGRADES MUTANT ATXN7 • JANER ET AL. 73
bodies that have strikingly different morphologies and protein 
composition. PML IV bodies are round and larger than PML 
III bodies, which are rod shaped. PML IV bodies were highly 
enriched in proteasome components. They contained subunits 
of the 19S complex, implicated in unfolding of the substrates, 
as well as subunits of the 20S catalytic core complex. PML IV
bodies also colocalized with the chaperone Hsp40 and poly-
ubiquitinylated proteins and thus resemble clastosomes, a subset 
of endogenous PML bodies enriched in UPS components, sug-
gested to be sites where nuclear proteins are degraded (Lafarga 
et al., 2002). Thus, endogenous PML IV appears to be a com-
ponent of endogenous clastosomes. Whether they also contain 
other isoforms of PML remains to be determined.
Interestingly, only overexpressed PML IV relocalized en-
dogenous as well as exogenous wild-type and mutant ATXN7 to 
PML IV bodies. Consequently, because of the presence of UPS 
components, PML IV actively increased the degradation of the 
soluble form of mutant ATXN7, which led to the disappearance 
of SDS-insoluble aggregates. We further demonstrated that the 
PML IV–dependent degradation of mutant ATXN7 is mediated 
by the proteasome, showing for the fi  rst time that exogenously 
expressed PML IV clastosomes indeed degrade a substrate, in 
our case, mutant ATXN7.
Time-lapse experiments showed that PML IV acts on the 
soluble form of mutant ATXN7 to recruit it to PML IV bodies. 
Correspondingly, soluble PML IV physically interacts with the 
soluble forms of mutant and wild-type ATXN7. This suggests 
that PML IV convoys the soluble forms of ATXN7 to the bod-
ies, where they are degraded by the UPS components, thus pre-
venting the deleterious accumulation of mutant ATXN7. How 
PML IV selects the substrates for degradation remains to be 
elucidated. Interestingly, ATXN7 does not interact with PML 
III (unpublished data) and, consequently, it is not recruited to 
PML III bodies. However, the immediate early gene X1 (IEX-1), 
a stress response gene involved in apoptosis, was shown to 
  colocalize with both PML III and IV and to coimmunoprecipi-
tate with PML III but not PML IV (Kruse et al., 2005). These 
authors noted on Western blots positive coregulation of PML 
III with IEX-1 but a negative coregulation of PML IV. IEX-1 
might therefore be another nuclear substrate for PML IV clas-
tosomes. An investigation of how ATXN7 interacts with PML 
IV, directly or indirectly, might provide a clue as to how PML 
IV selects its substrates.
Figure 10.  𝗃-INF treatment leads to the degradation of mutant ATXN7 
and the disappearance of aggregates. (A) β-INF treatment of COS-7 cells, 
untransfected (a and b) or expressing FL-74Q (c–h). β-INF increases the 
number and size of PML bodies (red) in untransfected cells (a and b). 
FL-74Q aggregates colocalized with some endogenous PML bodies (c–e, 
arrowheads). β-INF treatment increases both the number and size of PML 
bodies colocalized with mutant ATXN7 (f–h). Conventional ﬂ  uorescence 
was used. Bars, 5 μm. (B) RT-PCR with primers speciﬁ  c to PML IV shows that 
β-INF increases the expression of endogenous PML IV mRNA in nontrans-
fected (NT) cells (compare lanes 1 and 2), the levels of which are com-
pared with overexpressed PML IV (positive control; lane 3) and 
overexpressed PML III (negative control; lane 4). The reference transcript 
cyclophilin A (Cyclo A) was ampliﬁ  ed in parallel. (C–E) β-INF induces the 
expression of multiple isoforms of PML. β-INF does not affect the level of 
endogenous ATXN7 (C) but decreases the levels of transfected wild-type 
(D) and mutant ATXN7 (E). (F) PML-dependent degradation of ATXN7 
  induced by β-INF is inhibited by MG132, showing that it is mediated by the 
proteasome. (G, left) Filter assay shows that ATXN7 aggregates disappear 
in β-INF–treated cells, but an insoluble PML-containing fraction appears 
(lane 2). (right) Insoluble PML material was observed either when PML IV 
was expressed (lane 3) or when NT cells were treated with β-INF (lane 2), 
but not when PML III was expressed (lane 4).JCB • VOLUME 174 • NUMBER 1 • 2006  74
The SDS-insoluble structures formed by PML IV, consis-
tent with the fact that PML can self-interact and oligomerize 
(Kastner et al., 1992; Grignani et al., 1996; Jensen et al., 2001), 
might serve as a scaffold to bring together both the actors of 
the UPS and the substrates to be degraded. When the level of 
PML IV is increased by exogenous expression, the composi-
tion of the PML bodies changes, leading to the formation 
of enlarged clastosomes. This increases the capacity of the 
  nucleus to degrade specifi  c substrates, such as toxic polyQ 
  protein. Others have shown that proteasome-dependent protein 
degradation occurs in nucleoplasmic foci that partially overlap 
or juxtapose with splicing speckles and PML bodies (Rockel 
et al., 2005). In a very recent study, a novel GTPase CRAG 
(CRAM-associated GTPase) induced, under cellular stress, an 
interaction with PML that formed the enlarged ring structures 
typical of PML bodies (Qin et al., 2006). Interestingly, it was 
shown that polyQ accumulation and oxydative stress triggered 
association of CRAG and polyQ in the cytoplasm before trans-
location to the nucleus. Once inside the nucleus, CRAG pro-
moted the degradation of polyQ in PML bodies. It would be 
interesting to know whether CRAG was also implicated in the 
formation of PML IV bodies in our cell culture model, or 
whether activation of CRAG by experimental stress can con-
vert endogenous PML bodies that do not degrade ATXN7 to 
degradation-competent bodies, in the absence of overexpres-
sion or β-INF treatment.
Our study with cadmium showed, for the fi  rst time, that 
some endogenous PML bodies, presumably endogenous clasto-
somes, actively participate in the degradation of mutant ATXN7 
and, when disrupted, increase the amount of ATXN7 in cells. 
The slight increase in the amount of ATXN7 observed when 
PML III was overexpressed might also explain the disorganiza-
tion of endogenous clastosomes or a change in their  composition. 
These observations also suggest that endogenous clastosomes 
are not suffi  ciently active to prevent the aggregation of mutant 
ATXN7. The inhibitory effects on aggregation of increased 
PML IV expression raises the question of whether this would 
provide the basis of an interesting therapeutic strategy to treat 
SCA7 or other polyQ disorders.
In the brains of patients, endogenous clastosomes might 
prevent the accumulation of mutant proteins for several decades 
before onset of aggregation. Later in the pathogenic process, 
the balance between clastosome activity and the level of accu-
mulating polyQ proteins might be altered as a result of the dis-
ease process or a decrease in proteasome or chaperone activity 
during aging (Grune et al., 2004; Proctor et al., 2005), leading 
to the formation of polyQ aggregates. Because the mutant pro-
teins are concentrated in the clastosomes, this might even be a 
site where the aggregation of proteolytic fragments of the pro-
teins begins. The colocalization of PML bodies and small polyQ 
aggregates in the brain of patients and animal models supports 
this hypothesis.
β-INF increased the number and size of PML bodies and 
decreased the levels of both soluble and aggregated mutant 
ATXN7. Although the debate concerning the relative contribu-
tions of soluble and aggregated polyQ proteins to cellular toxicity 
has not yet been resolved (Michalik and Van Broeckhoven, 2003), 
the reduction of either form of the protein could be benefi  cial 
to cells. The observation that only mutant but not endogenous 
ATXN7 is degraded in the presence of β-INF, which is an 
  approved drug used in the treatment of multiple sclerosis (Javed 
and Reder, 2006), reinforces the hypothesis that this substance 
may have therapeutic value, as it would not eliminate functional 
ATXN7. However, it affected the aggregation of mutant ATXN7 
in cell cultures only when treatment began before or shortly 
  after transfection with the ATXN7 constructs. This is consistent 
with the action of PML IV on the soluble form of mutant 
ATXN7 but not on preexisting aggregates, raising the question 
of when in the course of SCA7 or other polyQ diseases an 
  effective therapy might be initiated. This should be explored in 
animal models.
In conclusion, our study shows that the capacity of the 
  nucleus to degrade specifi  c protein substrates is intimately linked 
to the level and composition of PML bodies. In addition to pro-
viding a molecular basis for the accumulation of certain mutant 
proteins in the nucleus, these fi  ndings also suggest that protein 
degradation through clastosomes can be potentiated to prevent 
the nuclear accumulation of undesirable proteins, such as those 
with expanded polyQ, raising the hopes that this mechanism 
will be adapted to therapeutic ends.
Materials and methods
Plasmids
The SCA7 constructs were previously described (Zander et al., 2001). 
FL-10Q and -74Q, cloned in pCDNA3, contain the full-length wild-type or 
expanded ATXN7 cDNA, respectively, with FLAG tags at the COOH terminus. 
FL-74Q contains, in addition, an HA tag at the NH2 terminus. Full-length 
and truncated ATXN7 containing 100Q were cloned in the pEGFP-N1 
  vector. A PML IV construct in the pTL2 vector was provided by P. Kastner 
(Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasbourg, 
France). PML IV was ampliﬁ  ed by PCR (see the supplemental text, available 
at http://www.jcb.org/cgi/content/full/jcb.200511045/DC1, for primer 
sequences) and cloned in pCDNA3. HcRFP-PML IV plasmid was generated 
by subcloning PML IV from pCDNA3 into pHcRed1-C1 vector (CLONTECH 
Laboratories, Inc.). All PML constructions were veriﬁ  ed by sequencing. The 
PML III construct in the pSG5 vector was given by A. Dejean (Institut 
  National de la Santé et de la Recherche Médicale, Paris, France).
RNA preparation and semiquantitative RT-PCR
RNA was extracted from whole-cell lysates of transfected or untransfected 
COS-7 cells, using the RNAeasy kit (QIAGEN), and cDNAs were synthe-
sized (ThermoScript RT-PCR System; Invitrogen) according to the manufac-
turer’s instructions. PCR was performed using primers speciﬁ  c for the genes 
of interest. PCR primers for ampliﬁ  cation of the SCA7 gene and for the PML IV–
speciﬁ  c 3′ end are given in the supplemental text. The cyclophilin A gene 
was used as the reference.
Cell culture, transfections, MG132, INF, and cadmium treatments
COS-7 cells were maintained in DME (Invitrogen) supplemented with 5% 
FBS and 100 IU/ml penicillin plus 100 μg/ml streptomycin. Cell lines 
were transfected with Lipofectamine-PLUS reagents (Invitrogen) as pre-
scribed. Unless otherwise speciﬁ  ed, cells were harvested or analyzed by 
immunoﬂ   uorescence 40–45 h after transfection. 2,000 IU/ml β-INF 
(Sigma-Aldrich) was added to the culture medium after plating and during 
transfection. Cadmium chloride (0.25–2 μM) was added during transfection. 
For proteasome inhibition, 5 μM MG132 was applied for 12 h at 25 h 
  after transfection.
Cultures of postmitotic neurons were prepared from the cortex of 
embryonic day 16 Wistar rats. Cells were extracted from the embryos and 
cultured with 1 μM MK801. Glial cell proliferation was stopped by adding 
1 μM cytosine arabinoside after 3 h. Primary cultures of cortical neurons 
were transfected 96 h after plating using Lipofectamine 2000 reagent 
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Western blot and ﬁ  lter retardation assay
Cells were harvested in PBS, pelleted, and lysed 30 min on ice in lysis buf-
fer containing 50 mM Tris, pH 8.8, 100 mM NaCl, 5 mM MgCl2, 0.5% 
NP-40, 1 mM EDTA, and 250 IU/ml benzonase (Merck) supplemented 
with a cocktail of protease inhibitors (Complete and Pefabloc; Roche). Total 
extracts were centrifuged at 13,000 rpm for 10 min at 4°C to separate sol-
uble proteins from aggregates and membranes. Supernatants (30 μg pro-
tein) were analyzed by Western blot. Pellets were washed with PBS and 
further incubated 30 min on ice in a pellet buffer containing 20 mM Tris, 
pH 8.0, 15 mM MgCl2, and 250 IU/ml benzonase. Protein concentrations 
(supernatant and pellet) were determined by Bradford assay (Bio-Rad Lab-
oratories). Samples were prepared for Western blot and for ﬁ  lter assay as 
previously described (Sittler et al., 1998; Wanker et al., 1999).
Pulse-chase analysis of ATXN7 turnover
Pulse-chase experiments were performed 17 h after transfection of COS-7 
cells with FL-74Q or with FL-74Q and PML IV. Cells were starved in methio-
nine/cysteine-free DME containing 2% FBS for 1 h. Cells were labeled for 
1 h with 200 μCi/ml of Pro-mix L-
35S labeling mix (GE Healthcare) in star-
vation medium. After the pulse, cells were rinsed twice and chased for the 
indicated periods of time in DME with 5% FBS. For immunoprecipitation, 
cells were lysed in 50 mM Tris, pH 8.0, 300 mM NaCl, 1% NP-40, 5% 
glycerol, and protease inhibitors. Equal amounts of labeled lysates (12 × 
10
6 cpm at time 0, determined after TCA precipitation) were immunopre-
cipitated with 3 μg anti-HA antibody (coupled to protein G–Sepharose 
beads) for 2 h at 4°C. Beads were washed four times with RIPA buffer, and 
bound proteins were directly denatured in 40 μl Laemmli buffer. Immuno-
precipitates were resolved on 4–12% SDS gradient gels (Invitrogen), visu-
alized by phosphoimaging, and quantiﬁ  ed with Aida analysis software 
(Raytest GmbH).
Immunoﬂ  uorescence
Cells plated on glass coverslips coated with poly-lysine (COS-7) or 
  polyethyleneimine (cortical neurons) were ﬁ   xed for 20 min with 4% 
  paraformaldehyde. Primary neurons were ﬁ  xed at 4 d after transfection. 
Permeabilization and further incubations with antibodies were done as 
previously described (Sittler et al., 1998). Cells were mounted with Fluoro-
mount-G, and samples were observed with a confocal microscope (SP1; 
Leica) equipped with a 63×/1.32 NA objective. Leica confocal software 
was used to acquire images. For conventional analysis, we used a 
  microscope (Axioplan-2; Carl Zeiss MicroImaging, Inc.) equipped with 
25×/0.80 NA, 63×/1.40 NA, and 100×/1.40 NA objectives and a 
cooled mono 12-bits camera (Evolution QEi; Explora Nova). Fluo’Up 
  software (Explora Nova) was used for image acquisition. 9-μm cryostat 
sections of ﬁ  xed retina were prepared and used for immunoﬂ  uorescence 
detection as described previously (Yvert et al., 2000).
Antibodies
For Western blot and immunoﬂ   uorescence analysis, we used the follow-
ing antibodies and concentrations: 1C1 mouse anti-ATXN7 (Yvert et al., 
2000) at 1:5,000 (Western blot) and 1:1,000 (immunoﬂ  uorescence), 
mouse anti-HA (Babco) at 1:10,000 (Western blot) and 1:4,000 (immuno-
ﬂ  uorescence), rabbit anti-ATXN7 (Afﬁ  nity BioReagents, Inc.) at 1:500 
  (immunoﬂ  uorescence), rabbit anti-ATXN7 afﬁ  nity-puriﬁ  ed polyclonal antibody 
1261 at 1:100 (immunoﬂ  uorescence on ﬁ  xed retina only), mouse anti-
PML (PG-M3; Santa Cruz Biotechnology, Inc.) at 1:500 (Western blot and 
  immunoﬂ  uorescence), rabbit anti-PML (H-238; Santa Cruz Biotechnology, 
Inc.) at 1:500 (Western blot and immunoﬂ  uorescence), chicken anti-PML 
antibody at 1:500 (immunoﬂ  uorescence on ﬁ  xed retina only; a gift from 
H. de Thé, Centre National de la Recherche Scientiﬁ  que, Paris, France), 
1C2 anti-polyQ monoclonal antibody at 1:2,000 (Western blot), anti-FMRP 
1C3 antibody (Sittler et al., 1996) at 1:1,000 (Western blot), mouse anti-
polyubiquitinylated proteins (FK2; BIOMOL Research Laboratories, Inc.) at 
1:1,000 (immunoﬂ  uorescence), rabbit anti-19S proteasome subunit S10a 
(PW-8225; BIOMOL Research Laboratories, Inc.) at 1:500 (immunoﬂ  uo-
rescence), rabbit anti-20S core (PW-8155; BIOMOL Research Labora-
tories, Inc.) at 1:1,000 (immunoﬂ  uorescence), rabbit anti-Hsp40 (SPA-400; 
StressGen Biotechnologies) at 1:2,000 (immunoﬂ  uorescence). For the ﬁ  lter 
assay, we used the same antibody concentrations as for Western blots. 
For immunoﬂ   uorescence, secondary antibodies were as follows: Alexa 
488–  conjugated goat anti–mouse or goat anti–rabbit IgG (Invitrogen) used 
at 1:500 and CY3-conjugated goat anti–mouse or goat anti–rabbit IgG 
(Jackson   ImmunoResearch Laboratories) used at 1:1,000. In Fig. 1, different 
secondary antibodies and dilutions were used: CY3-conjugated goat anti–
rabbit IgG (1:200) and FITC-conjugated goat anti–chicken IgG (1:150).
Time-lapse recordings
HeLa Kyoto cells (a gift from S. Narumiya, Kyoto University, Kyoto, Japan) 
grown on 35-mm microwell dishes (MatTek Corporation) were transfected 
with 1 μg FL-100Q-EGFP (expressing GFP-ATXN7 fusion protein) and 0.5 μg 
HcRFP-PML IV using FuGENE6 (Roche). At 6 h after transfection, cells were 
placed on the microscope in a chamber at 37°C and 5% CO2. Several 
cells showing low levels of GFP-ATXN7 were selected and monitored every 
10 min for 16 h. Images were acquired with an inverted microscope 
(DMIRE2; Leica) equipped with a 63×/1.35 NA objective and a camera 
(CoolSNAP fx; Roper Scientiﬁ  c). MetaMorph software (Molecular Devices) 
was used to control image acquisition and manipulation.
Coimmunoprecipitation
COS-7 cells were transfected in 90-mm culture dishes with PML IV and 
FL-74Q or -10Q. Cells were harvested 42–45 h after transfection and lysed 
on ice in 150 mM salt buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM 
EDTA, and 1% NP-40) supplemented with a cocktail of protease inhibitors 
(Complete and Pefabloc). Total extract was centrifuged at 13,000 rpm for 
10 min at 4°C, and the supernatant was precleared with protein A– or pro-
tein G–Sepharose beads (GE Healthcare) for 1 h at 4°C. Precleared super-
natant and protein A– or protein G–Sepharose beads coupled with the 
appropriate antibodies were incubated 2 h at 4°C on a rotating wheel for 
immunoprecipitation. Finally, the beads were washed ﬁ  ve times with 500 mM 
salt buffer (50 mM Tris, pH 8.0, 500 mM NaCl, 1 mM EDTA, and 1% 
NP-40; supplemented with protease inhibitors), and bound proteins were 
directly denatured by heating for 5 min at 95°C in 30 μl Laemmli buffer. 
Samples were analyzed by Western blot.
Electron microscopy
Cells were ﬁ  xed with 4% paraformaldehyde in phosphate buffer, pH 7.4, 
for 1 h on ice and then postﬁ  xed with 1% osmium tetroxyde and embedded 
in Epon 812 (Taab). Ultrathin sections (50 nm) placed on nickel grids were 
immunogold labeled after embedding. We used primary antibodies mouse 
monoclonal anti–ATXN7 1C1 at 1:200 and rabbit polyclonal anti-PML at 
1:250 and secondary antibodies conjugated to 10- or 15-nm gold particles 
(goat anti–mouse or goat anti–rabbit [Aurion]) at 1:100. After labeling, 
sections were postﬁ  xed in 1% glutaraldehyde and stained with uranyl ace-
tate and lead citrate (see detailed protocol in the supplemental text). Cells 
were examined with an electron microscope (1200EX; Jeol) at 80 kV.
Online supplemental material
Fig. S1 shows that PML IV bodies recruit 19S5a, 19S6b, and 20Sα2 pro-
teasome subunits. As a consequence, the colocalization of these actors of 
the protein degradation pathway with mutant ATXN7 strongly increases 
in double-transfected cells compared with cells expressing mutant ATXN7 
alone. Online supplemental material is available at http://www.jcb.
org/cgi/content/full/jcb.200511045/DC1.
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